Search the Newsreel

Bank of America Corp DE Raises Stock Position in Regency Centers Corporation $REG

Bank of America Corp DE increased its stake in Regency Centers Corporation (NASDAQ:REG) by 66.5% in the first quarter, now owning 719,536 shares valued at $54.4 million. Institutional investors hold 96.07% of the company's stock. Regency Centers also announced a quarterly dividend of $0.755 …

Regency Ceramics Ltd leads gainers in 'B' group

Regeneron Pharmaceuticals Inc (REGN) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Projeções de Resultados: Regeneron Pharmaceuticals Inc (REGN) — LPA e Crescimento de Receita

Regal Rexnord (RRX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 11 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Robert BarryChief Executive Officer - Aamir PaulExecutive Vice President and Chief Financial Officer - Rob Rehard TAKEAWAYS Net Sales -- $1,558.4 million …

Regal Rexnord Corp (RRX) Insider Sell: SVP, Corp. Controller and CAO Alexander Scarpelli Sells 170 Shares

Alexander Scarpelli, SVP, Corp. Controller and CAO of Regal Rexnord Corp (RRX), sold 170 shares of the company for approximately $29,961 on August 10, 2026. This sale contributes to a pattern of insider selling at RRX over the past year, with no insider purchases …

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) for alleged federal securities law violations. The lawsuit claims that REGENXBIO made materially false and misleading statements regarding the development and commercialization of RGX‑111 for severe MPS I. …

Regencell Bioscience (RGC) Short Interest & Short Float | Updated Aug 2026 $RGC

Regencell Bioscience (RGC) had a short interest of 903,042 shares as of July 31, 2026, which is a 2.91% decrease from the previous report. This represents 0.18% of its public float, with a short interest ratio of 4.1 days to cover. The article provides …

Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors

Regeneron Pharmaceuticals Inc. (REGN) stock fell by 1.37% to $797.00 on Tuesday, breaking a five-day winning streak. This underperformance occurred during a generally poor trading session, with the S&P 500 Index and Dow Jones Industrial Average also experiencing declines.

Regal Rexnord (RRX) accounting chief sells 170 shares, details SAR holdings

Alexander P. Scarpelli, Senior Vice President, Corporate Controller, and Chief Accounting Officer of Regal Rexnord (RRX), reported selling 170 shares of Common Stock at $176.238 per share on August 10, 2026. Following this transaction, he holds 3,274.286 Common shares directly. The report also details …

Regions Bank to invest millions in namesake Midtown Atlanta office tower

Regions Bank is expanding its presence in Midtown Atlanta by investing millions in its namesake office tower, Regions Plaza. The bank has extended its lease in the building and plans to hire additional staff. This move signifies Regions Bank's continued commitment to the Atlanta …

Regions promotes exec playing key role in branch-revamp plan

Key insight: Regions Financial is moving Kate Danella into a different C-suite role and promoting John Jordan to succeed her as head of consumer banking. What's at stake: The leadership shuffle is taking place as Regions speeds up the timeline for renovating its branch …

Regeneron Pharmaceuticals (REGN) Following Earnings And Buybacks, Is The Valuation Case Still Intact?

Regeneron Pharmaceuticals (REGN) has garnered investor attention after releasing its Q2 and six-month 2026 results, affirming a dividend, and detailing recent share repurchases. While the company's broad pipeline supports future revenue growth and analysts view it as 3% undervalued with a fair value of …

Regency Centers (REG) Releases Updated Investor Presentation

Regency Centers (REG) has released an updated investor presentation, providing a comprehensive overview of its business operations, strategic initiatives, and market positioning as a leading real estate investment trust specializing in grocery-anchored shopping centers. The presentation is accessible on the company's investor relations website …

Regaal Resources Q1 Results: Earnings Call Scheduled for August 17

Regency Centers publishes investor presentation on grocery-anchored shopping center portfolio and growth strategy

Regency Centers has published an investor presentation detailing its growth strategy centered on a grocery-anchored shopping center portfolio. The presentation highlights a portfolio of over 480 open-air shopping centers, strong occupancy rates, high grocery-anchored exposure, and a solid financial profile with favorable credit ratings …

Regions announces leadership changes as Dave Keenan plans retirement

Regions Financial Corp. announced leadership changes as Chief Administrative Officer Dave Keenan plans to retire at the end of 2026. Kate Danella will succeed Keenan as chief administrative officer, John Jordan will lead Consumer Banking, and Angela Santone will report directly to the CEO. …

Form 8K Regency Centers Corp For: 11 August By Investing.com

This article reports on the filing of a Form 8K by Regency

REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?

The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index …

REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit

Hagens Berman Sobol Shapiro LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals (NASDAQ: REGN) after a Phase 3 clinical trial for a melanoma treatment failed, causing an $11 billion market cap wipeout. The lawsuit alleges that Regeneron made misleading statements and …

Regions C suite leader to retire as leadership shifts take shape

A longtime leader at Regions Bank, Dave Keenan, will be retiring later this year. He will transition to an advisory role in September and work until year-end to ensure a smooth transition of his responsibilities as chief administrative officer. This retirement is part of …

REGN DEADLINE: The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline

The Gross Law Firm is reminding investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) about an upcoming securities class action deadline of September 14, 2026. The lawsuit alleges that Regeneron made false and misleading statements regarding its Phase III Fianlimab-Libtayo Study, leading to significant stock …

Regions Financial Announces Executive Leadership Succession Plan

Regions Financial (RF) announced a leadership succession plan, with executive Dave Keenan retiring at the end of 2026 and transitioning to an advisory role. Kate Danella will become Chief Administrative Officer, John Jordan will lead Consumer Banking, and Angela Santone will report directly to …

Regions Financial announces leadership changes as CAO retires By Investing.com

Regions Financial Corp. (NYSE:RF) announced leadership changes as Chief Administrative Officer Dave Keenan plans to retire at the end of 2026. Kate Danella, currently Head of Consumer Banking, will succeed Keenan, while John Jordan will take over Danella's previous role. Angela Santone, Chief People …

Regions Financial Announces Upcoming Retirement of Dave Keenan and New Executive Leadership Appointments

Regions Financial Corp. announced that Chief Administrative Officer Dave Keenan will retire at the end of 2026 after over two decades with the company. Kate Danella, currently head of Consumer Banking, will succeed Keenan, while John Jordan will take over as head of Consumer …

After More Than 20 Years at Regions, Dave Keenan Will Retire

Regions Financial Corp. announced that Chief Administrative Officer Dave Keenan will retire at the end of 2026 after more than two decades of service. Kate Danella, currently head of Consumer Banking, will succeed Keenan, while John Jordan will take over Danella's role as head …

Jefferies Adjusts Price Target on Regency Centers to $102 From $103, Maintains Buy Rating

Jefferies has adjusted its price target for Regency Centers (REG) to $102, down from $103, while maintaining a Buy rating on the stock. This follows other recent analyst adjustments for Regency Centers, with BMO Capital raising its target to $92 and Argus raising theirs …

PensionDanmark Pensionsforsikringsaktieselskab Boosts Stock Holdings in Regency Centers Corporation $REG

PensionDanmark Pensionsforsikringsaktieselskab significantly increased its stake in Regency Centers Corporation (NASDAQ:REG) by 344% in the second quarter, bringing its total holdings to 22,155 shares valued at $1.77 million. Institutional investors now own 96.07% of the REIT, reflecting a strong collective interest. Analysts largely maintain …

NewEdge Advisors LLC Has $5.88 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

NewEdge Advisors LLC recently reduced its stake in Regeneron Pharmaceuticals, Inc. by 23.3% in the first quarter, now holding 7,610 shares valued at $5.88 million. Despite this, institutional investors collectively own a significant 83.31% of the company's stock. Regeneron reported strong quarterly earnings of …

Longtime Regions executive retires, company announces leadership changes

Regions Financial's Chief Administrative Officer Dave Keenan is set to retire at the end of the year after more than two decades with the company. Kate Danella will succeed

IRIS RegTech Standalone June 2026 Net Sales at Rs 30.86 crore, up 9.54% Y-o-Y

¿4% Infravalorada? Regeneron Pharmaceuticals (REGN) Tras Sus Resultados Y Recompras

Saregama India to participate in EMKAY Confluence 2026 investor conference

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Regeneron Pharmaceuticals (NASDAQ:REGN) has received a consensus "Moderate Buy" rating from analysts, with 16 recommending buy, 10 hold, and one strong-buy. The company recently surpassed quarterly earnings and revenue expectations, reporting $14.29 EPS against an estimated $10.16 and $4.29 billion in revenue, a 16.7% …

H.C. Wainwright lowers Regenxbio stock price target on equity offering

H.C. Wainwright has lowered its price target for Regenxbio (NASDAQ:RGNX) to $23 from $26, while maintaining a Buy rating, following the company's public offering of common stock in July 2026. This adjustment comes as Regenxbio reported Q2 2026 revenue of $108 million, including a …

Regal Partners Global Investments Buys Back 80,160 Shares in Daily On-Market Update